Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
Biotech’s important first-quarter data
Kodiak, Biomarin and Argenx prepare for clinical catalysts.